Education
About Us
Working with TipRanks
Follow Us
Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
AVR Stock Chart & Stats
$5.61
-$0.12(-2.09%)
At close: 4:00 PM EST
$5.61
-$0.12(-2.09%)
Day’s Range― - ―
52-Week Range$2.34 - $8.79
Previous Close$5.88
Volume157.53K
Average Volume (3M)151.40K
Market Cap
$226.17M
Enterprise Value$177.84M
Total Cash (Recent Filing)$9.12M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Mar 18, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding41,197,570
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.80
Price to Sales (P/S)41.81
P/FCF Ratio-1.78
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue83.14
Enterprise Value/Gross Profit122.37
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$17.33Price Target Upside208.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical HemodynamicsDurAVR achieved very low transvalvular gradients, large effective orifice areas, and no moderate or severe paravalvular leak, suggesting superior blood flow characteristics that can reduce symptom burden and need for reintervention.
Regulatory ProgressFDA IDE approval for the PARADIGM PMA trial enables initiation of US enrollment and represents a key regulatory milestone that advances the device toward potential market authorization.
Trial Design And Competitive DifferentiationThe randomized, international PARADIGM trial compares DurAVR head to head with incumbent TAVR platforms and is structured to highlight laminar flow restoration and long term durability, which could drive physician adoption if superiority is demonstrated.
Bears Say
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $2.34 and its highest was $8.79 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $226.17M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
Anteris Technologies Global Corp.’s upcoming earnings report date is Mar 18, 2026 which is in 34 days.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Anteris Technologies Global Corp. released its earnings results on Nov 12, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.542 by -$0.078.
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate is -0.5.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 41,197,570 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Anteris Technologies Global Corp. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.542. Following the earnings report the stock price went down -2.571%.
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anteris Technologies Global Corp. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.33 (208.91% Upside)
$17.33 (208.91% Upside)
Insider Transactions
Bought Shares
Worth $28.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 21.8%
Last 30 Days ▲ 21.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.53%
12-Months-Change
Fundamentals
Return on Equity
-2462.70%
Trailing 12-Months
Asset Growth
-9.61%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$17.33
▲(208.91% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Inogen
―
Treace Medical Concepts
―
Rapid Micro Biosystems
―
Ownership Overview
0.98% Insiders
2.83% Mutual Funds
37.87% Other Institutional Investors
53.85% Public Companies and
Individual Investors